Syneos Health, Inc. Class A Common Stock Underwriting AgreementUnderwriting Agreement • June 4th, 2021 • Syneos Health, Inc. • Services-commercial physical & biological research • New York
The stockholders named in Schedule II hereto (the “Selling Stockholders”) of Syneos Health, Inc., a Delaware corporation (the “Company”), propose, subject to the terms and conditions stated herein, to sell to BofA Securities, Inc. (“BofA Securities”) as set forth in Schedule I hereto (the “Underwriter”) an aggregate of 10,851,676 shares (the “Shares”) of Class A Common Stock, par value $0.01 (“Stock”) of the Company.
STOCK REPURCHASE AGREEMENTStock Repurchase Agreement • June 4th, 2021 • Syneos Health, Inc. • Services-commercial physical & biological research • New York
THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of June 1, 2021 by and between Syneos Health, Inc., a Delaware corporation (the “Company”), Thomas H. Lee Equity Fund VII, L.P., Thomas H. Lee Parallel Fund VII, L.P., THL Executive Fund VII, L.P., THL Fund VII Coinvestment Partners, L.P., THL Equity Fund VII Investors (inVentiv), L.P., Thomas H. Lee Equity Fund VI (2019), L.P., THL Fund VI (2019) Coinvestment Partners, L.P., THL Managers VI, LLC and THL Managers VII, LLC (collectively, the “THL Funds”) and Double Eagle Investor Holdings, L.P. and Advent International GPE VIII-C Limited Partnership (together, the “Advent Funds”, and collectively with the THL Funds, the “Sellers”).
